Page last updated: 2024-09-02

acetylleucyl-leucyl-norleucinal and (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid

acetylleucyl-leucyl-norleucinal has been researched along with (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid in 1 studies

Compound Research Comparison

Studies
(acetylleucyl-leucyl-norleucinal)
Trials
(acetylleucyl-leucyl-norleucinal)
Recent Studies (post-2010)
(acetylleucyl-leucyl-norleucinal)
Studies
((6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid)
Trials
((6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid)
Recent Studies (post-2010) ((6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid)
32105332012

Protein Interaction Comparison

ProteinTaxonomyacetylleucyl-leucyl-norleucinal (IC50)(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid (IC50)
3-hydroxy-3-methylglutaryl-coenzyme A reductaseHomo sapiens (human)0.0142
Cytochrome P450 2C9 Homo sapiens (human)0.4
Insulin receptor Rattus norvegicus (Norway rat)0.0004
Prostaglandin G/H synthase 2Homo sapiens (human)0.0004
3-hydroxy-3-methylglutaryl-coenzyme A reductase Rattus norvegicus (Norway rat)0.003

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H1

Other Studies

1 other study(ies) available for acetylleucyl-leucyl-norleucinal and (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid

ArticleYear
Identifying off-target effects and hidden phenotypes of drugs in human cells.
    Nature chemical biology, 2006, Volume: 2, Issue:6

    Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship

2006